The potential for selective pharmacological therapies through biased receptor signaling

BMC Pharmacology and Toxicology

Volumn 13, Issue , 2012, Pages

  Kenakin, Terry ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CALCITONIN; CYCLIC AMP; DOPAMINE RECEPTOR STIMULATING AGENT; GHRELIN RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; INOSITOL PHOSPHATE; KAPPA OPIATE RECEPTOR; RANTES; RECEPTOR; S6 KINASE; SEROTONIN; CELL SURFACE RECEPTOR;

ADDICTION; AGONIST; CELL SURFACE; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DIABETES MELLITUS; DISSOCIATION CONSTANT; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENETIC TRANSFECTION; HEART FAILURE; HEART PERFORMANCE; HEART STROKE VOLUME; HYPERTENSION; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; INTERNALIZATION; KIDNEY FUNCTION; KNOCKOUT GENE; LLC PK1 CELL; LUNG SMALL CELL CANCER; MEAN ARTERIAL PRESSURE; MICHAELIS CONSTANT; NONHUMAN; OSTEOPOROSIS; PARKINSONISM; PHENOTYPE; PREDICTION; PSYCHOSIS; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; SIGNAL TRANSDUCTION; ANIMAL; DRUG POTENTIATION; DRUG THERAPY; HUMAN; METABOLISM;

ANIMALS; DRUG THERAPY; HUMANS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84872048999     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-13-3     Document Type: Review

References (82)

1. Black JW, Leff P. Operational models of pharmacological agonist. Proc R Soc Lond [Biol] 1983, 220:141-16. 2.
2. Roth BL, Chuang D-M. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987, 41:1051-1064. 10.1016/0024-3205(87)90621-7, 2441225.
3. Mailman RB, Lawler CP, Lewis MM, Blake B. Functional effects of novel dopamine ligands: Dihydrexidine and Parkinson's disease as a first step. Dopamine Receptor Subtypes: From Basic Science to Clinical Application 1998, 53-65. IOS Press, New York, Jenner P, Demirdamar R.
4. Roerig SC, Loh HH, Law PY. Identification of three separate guanine nucleotide- binding proteins that interact with the δ-opioid receptor in NG108-15 X glioma hybrid cells. Mol. Pharmacol. 1992, 41:822.831.
5. Fisher A, Heldman E, Gurwitz D, Haring R, Barak D, Meshulam H, Marciano D, Brandeis R, Pittel Z, Segal M, et al. Selective signaling via unique M1 muscarinic agonists. Ann N Y Acad Sci 1993, 695:300-303. 10.1111/j.1749-6632.1993.tb23070.x, 8239299.
6. Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. Eur J Pharmacol 1994, 267:21-31. 10.1016/0922-4106(94)90220-8, 8206127.
7. Ward JS, Merrit L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD, Mitch CH, Deeter JB, Peters SC, Sheardown MJ. Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazacycles. J Med Chem 1995, 38:3469-3481. 10.1021/jm00018a007, 7658434.
8. Heldman E, Barg J, Fisher A, Levy R, Pittel Z, Zimlichman R, Kushnir M, Vogel Z. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. Eur J Pharmacol 1996, 297:283-291. 10.1016/0014-2999(95)00745-8, 8666061.
9. Lawler CP, Prioleua C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes. Neuro psychopharmacology 1999, 20:612-627.
10. Kenakin TP, Ambrose JR, Irving PE. The relative efficiency of -adrenoceptor coupling to myocardial inotropy and diastolic relaxation: Organ selective treatment for diastolic dysfunction. J Pharmacol Exp Ther 1991, 257:1189-1197.
11. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997, 51:357-362.
12. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001, 56:441-451. 10.1016/S0361-9230(01)00623-2, 11750789.
13. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburgt PH, Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature (London) 1993, 365:170-175.
14. Watson C, Chen G, Irving PE, Way J, Chen W-J, Kenakin TP. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: Implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 2000, 58:1230-1238.
15. Kenakin TP. Agonist-receptor efficacy II: Agonist-trafficking of receptor signals. Trends PharmacolSci 1995, 16:232-38.
16. Kenakin TP, Miller LJ. Seven transmembrane receptors as shape shifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010, 62:265-304. 10.1124/pr.108.000992, 2879912, 20392808.
17. Perez DM, Karnick SS. Multiple signaling states of G-protein coupled receptors. Pharmacol Rev 2005, 57:147-61. 10.1124/pr.57.2.2, 15914464.
18. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396. 10.1016/j.tips.2007.06.002, 2958218, 17629962.
19. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR Modulators: Taking Advantage of Permissive Receptor Pharmacology. Trends PharmacolSci 2007, 28:382-389.
20. Kenakin TP. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011, 336:296-302. 10.1124/jpet.110.173948, 21030484.
21. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D-1 receptors linked to adenylatecyclase. J Pharmacol Expx Ther 2002, 301:1166-1178.
22. Berg KA, Maayani S, Goldfarb J, Scaramelli C, Leff P, Clarke WP. Effect pathway-dependent relative efficacy at serotonin type 2A and 2 C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998, 54:94-104.
23. Baneres J-L, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaret J. Molecular characterization of a purified 5-HT4 receptor. J Biol Chem 2005, 280:20253-20260. 10.1074/jbc.M412009200, 15774473.
24. Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M. Conformational rearrangements and signaling cascades invovled in ligand-based mitogen-activated protein kinase signaling through the β1-adrenergic receptor. Mol Pharmacol 2008, 74:162-172. 10.1124/mol.107.043893, 18403719.
25. Georgieva T, Devanathan S, Stropova D, Park PK, Salamon Z, Tollin G, Hruby VJ, Roeske WR, Yamamura HI, Varga E. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 2008, 581:19-29. 10.1016/j.ejphar.2007.11.053, 2279194, 18162180.
26. Gether U, Lin S, Kobilka BK. Fluorescent labeling of purified β2-adrenergic receptor: evidence for ligand specific conformational changes. J Biol Chem 1995, 270:28268-28275. 10.1074/jbc.270.47.28268, 7499324.
27. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, Kobilka BK. Functionally different agonists produce distinct conformations in G-protein coupling domains of the β2-adrenergic receptor. J Biol Chem 2001, 276:24433-24436. 10.1074/jbc.C100162200, 11320077.
28. Granier S, Kim T, Shafer AM, Ratnala VR, Fung JJ, Zare RN, Kobilka B. Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 2007, 282:13895-13905. 10.1074/jbc.M611904200, 17347144.
29. Hruby VJ, Tollin G. Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities. Curr OpinPharmacol 2007, 7:507-514.
30. Kobilka B, Gether U. Use of fluorescence spectroscopy to study conformational changes in the beta-adrenoceptor. Methods Enzymol 2002, 343:170-182.
31. Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Viladarga J-P, Bunemann M. Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol 2008, 153:S125-S132. 2268076, 18193071.
32. Okada T, Palczewski K. Crystal structure of rhodopsin: Implications for vision and beyond. Curr Opin Struc Biol 2001, 11:420-426.
33. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. Sequential Binding of Agonists to the β2 Adrenoceptor: Kinetic evidence for intermediate conformational states. J Biol Chem 2004, 279:686-691.
34. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, et al. Probing the β2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Bio Chem 2005, 280:22165-22171.
35. Tutor A, Penela P, Mayor F. Anti-β1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 2007, 76:51-60. 10.1016/j.cardiores.2007.05.022, 17628514.
36. Vilardaga JP, Bunemann M, Krasel C, Castro M, Lohse MJ. Measurement of the millisecond activation switch of G-protein-coupled receptors in living cells. Nat Biotechnol 2003, 21:807-812. 10.1038/nbt838, 12808462.
37. Viladarga JP, Steinmeyer R, Harms GS, Lohse MJ. Molecular basis of inverse agonism in a G-protein coupled receptor. Nat Chem Biol 2005, 1:25-28. 10.1038/nchembio705, 16407989.
38. Zurn A, Zabel U, Viladarga JP, Schindlein H, Lohse MJ, Hoffmann C. Fluorescence resonance energy transfer analysis of α2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 2009, 75:534-541. 10.1124/mol.108.052399, 19106230.
39. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K. Biased signaling pathways in β2-adrenergic receptor characterized by 19 F-NMR. Science 2012, 335:1106-1110. 10.1126/science.1215802, 22267580.
40. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, et al. Crystal structure of the 2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-557. 10.1038/nature10361, 3184188, 21772288.
41. Yan F, Mosier PD, Westkaemper RB, Roth BL. Gα-subunits differentially alter the conformation and agonist affinity of k-opioid receptors. Biochem 2008, 47:1567-1578.
42. Mary S, Damian M, Louet M, Floquet N, Fehrentz J-A, Marie J, Martinez J, Baneres J-L. Ligands and signaling proteins govern the conformational landscape explored by G protein-coupled receptor. Proc Natl Acad Sci USA 2012, /pnas1119881109.
43. Figueroa KW, Griffin MT, Ehlert FJ. Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 2009, 328:331-342. 10.1124/jpet.108.145219, 2644050,2644050, 18824613.
44. Kenakin TP, Watson C, Muniz-Medina V, Christopoulos, Novick S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 2012, 3:193-203. 10.1021/cn200111m, 22860188.
45. Raehal KM, Walker JKL, Bohn LM. Morphine side effects in β-arrestin 2 knockout mice. J Pharmacol Exp Ther 2005, 314:1195-1201. 10.1124/jpet.105.087254, 15917400.
46. Bohn L, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin F-T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498. 10.1126/science.286.5449.2495, 10617462.
47. Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, Rothman RB. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence. SYNAPSE 2007, 61:166.175.
48. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM. An opioid agonist that does not induce mu opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 2007, 71:549-557.
49. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent beta-arrestin 2 and G protein mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003, 100:10782-10787. 10.1073/pnas.1834556100, 196880, 12949261.
50. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, Lefkowitz RJ. β-arrestin-2 mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA 2006, 103:16284-16289. 10.1073/pnas.0607583103, 1637574, 17060617.
51. Aplin M, Bonde MM, Hansen JL. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J Mol Cell Cardiol 2009, 46:15-24. 10.1016/j.yjmcc.2008.09.123, 18848837.
52. Violin JD, Lekowitz RJ. β-arrestin-biased ligands at seven transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422. 10.1016/j.tips.2007.06.006, 17644195.
53. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle H, Yu X, Kupershmid S, et al. Cardiac-specific overexpression of At1 receptor mutant lacking Gaq/Gai coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005, 115:3045-3056. 10.1172/JCI25330, 1265872, 16276415.
54. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol, Exp Ther 2010, 335:572-579.
55. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC. Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II type 1 receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011, 4:770-778. 10.1161/CIRCHEARTFAILURE.111.962571, 21835984.
56. Mack M, Luckow B, Nelson PJ, Cihack J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, et al. Aminooxypetnane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism mechanism for HIV infectivity. J Exp Med 1998, 187:1215-1224. 10.1084/jem.187.8.1215, 2212227, 9547333.
57. Walters RW, Shukla A, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muelbauer MJ, Whalen EJ, Lefkowitz RJ. β-arrestin 1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009, 119:1312-1321. 10.1172/JCI36806, 2673863, 19349687.
58. Richman JG, Kanetemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Chm L, Maciejewski-Lenoir D, et al. Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 2008, 283:6232-6240. 10.1074/jbc.M705759200, 18174174.
59. Shizukuda Y, Buttrick PM. Subtype specific roles of β-adrenergic receptors in apoptosis of adult rat ventricular myocytes. J Mol Cell Cardiol 2002, 34:823-831. 10.1006/jmcc.2002.2020, 12099721.
60. Metra M, Dei Cas L, di Lenarda A, Poole-Wilson P. Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?. Heart fail Rev 2004, 9:123-130.
61. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Shenoy SK, Lefkowitz RJ. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 2007, 104:16657-16662. 10.1073/pnas.0707936104, 2034221, 17925438.
62. Galeotti N, Malmberg-Aiello P, Bartolini A, Schunack W, Ghelardini C. H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway. Neuropharmacol 2004, 47:295-303.
63. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 2008, 105:1079-1084. 10.1073/pnas.0708862105, 2242710, 18195357.
64. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growthEndocr. Rev 1992, 13:596-611.
65. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396. 10.1016/j.tips.2007.06.002, 2958218, 17629962.
66. Grady MA, Gasperoni TL, Kirkpatrick P. Aripiprazole. Nat Rev Drug Disc 2003, 2:427-428.
67. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripirazole has functionally selective action at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacol 2007, 32:67-77.
68. MacKinnon AC, Tufail-Hanif U, Lucas CD, Jodrell D, Haslett C, Sethi T. Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-inducedgrowth inhibition. Br J Cancer 2005, 92:522-531. 2362091, 15685238.
69. Gesty-Palmer D, Flanner P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, Luttrell LM. A β-Arrestin-Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation. Sci Transl 2009, 1:1ra1.
70. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 2008, 105:1079-1084. 10.1073/pnas.0708862105, 2242710, 18195357.
71. Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT, Manen D, Bouxsein ML. Bone response to intermittent parathyroid hormone is altered in mice bull for (beta) arrestin 2. Endocrinol 2005, 146:1854-1862.
72. Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goodard WA, Mailman RB. Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors. Neuropharmacol 2007, 52:562-575.
73. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu J-C, Olefsky JM. β-arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells. Proc Natl Acad Sci USA 2008, 105:6614-6619. 10.1073/pnas.0710402105, 2373360, 18445652.
74. Ji S-P, Zhang Y, van Cleemput J, Jiang W, Liao M, Li L, Wan Q, Backstrom JR, Zhang X. Disruption of PTEN coupling with 5-HT2C receptors supporesses behavioral responses induced by drugs of abuse. Nat Med 2006, 12:324-329. 10.1038/nm1349, 16474401.
75. Willins DL, Berry SE, Alsayegh L, Backstrom JR, Sanders-Bush E, Friedman L, Roth BL. Clozapine and other 5-HT2A antagonists alter the subcellular distribution of 5-hydroxytryptamine 2A receptors in vitro and in vivo. Neuroscience 1999, 91:599-606. 10.1016/S0306-4522(98)00653-8, 10366017.
76. Strachan RT, Sciaky N, Cronan MR, Kroeze WK, Roth BL. Genetic deletion of p90 Ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine2A serotonin receptor functional selectivity. Mol Pharmacol 2010, 77:327-338. 10.1124/mol.109.061440, 2835420, 19933401.
77. Fraunfelder H, Parak F, Young RD. Conformational substrates in proteins. Annu Rev BiophysBiophysChem 1988, 17:451-79.
78. Fraunfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991, 254:1598-1603. 10.1126/science.1749933, 1749933.
79. Woodward C. Is the slow-exchange core the protein folding core?Trends Biochem. Sci 1993, 18:359-60.
80. Hilser J, Freire E. Predicting the equilibrium protein folding pathway: structure-based analysis of staphylococcal nuclease. Protein StructFunctGenet 1997, 27:171-83.
81. Hilser VJ, Garcia-Moreno EB, Oas TG, Kapp G, Whitten ST. A statistical thermodynamic model of protein ensembles. Chem Rev 2006, 106:1545-1558. 10.1021/cr040423+, 16683744.
82. Kenakin TP. Efficacy at G Protein Coupled Receptors. Annual Review of Pharmacology and Toxicology 2002, 42:349-379. 10.1146/annurev.pharmtox.42.091401.113012, 11807176.